TY - JOUR
T1 - Effects of probiotic on gut microbiota in children with acute diarrhea
T2 - A pilot study
AU - Samsudin, Dion Darius
AU - Firmansyah, Agus
AU - Hidayati, Eka Laksmi
AU - Yuniar, Irene
AU - Karyanti, Mulya Rahma
AU - Roeslani, Rosalina Dewi
N1 - Funding Information:
The probiotics used for this pilot study was provided by Novell Pharmaceutical Laboratories, which also provided partial funding for this study.
Funding Information:
This work was supported by Daniel Effendi, MD, the head of Child Health Department in Budhi Asih District Hospital, Jakarta. Special thanks to Fahmi Kurniawan, MD for help in data collection, and all the nurses and professional health personnel in the Pediatrics Ward.
Funding Information:
This work was supported by Novell Pharmaceutical Laboratories, which provided in partial funding for this pilot study.
Publisher Copyright:
© 2020, Indonesian Pediatric Society Publishing House. All rights reserved.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Background Acute diarrhea is a common health problem in Indo-nesia. During acute diarrhea, changes in gut microbiota are marked by decrease beneficial microbes Bifidobacterium and Lactobacillus, and increased pathogenic bacteria Enterobacter and Clostridium. Such microbial imbalances are known as dysbiosis. Treatment with probiotics may help repair dysbiosis, quicken healing time, and decrease complications. Objective To assess for dysbiosis during acute diarrhea, and determine if it can be normalized by probiotic treatment. Methods This placebo-controlled, unblinded clinical trial was performed in Budhi Asih District Hospital, Jakarta, from January to March 2018. Twenty-four children age 6-24 months with acute diarrhea and 12 healthy children were enrolled. First fecal specimen was collected for all subjects and analyzed using non-culture real time PCR to count the population of Lactobacillus, Bifidobacterium, Enterobacter, Clostridium, and all bacteria. Children with diarrhea were assigned to probiotic or placebo treatment for 5 days and the second fecal specimen was analyzed two weeks after the diarrhea subsided. Results Prior to treatment, significant higher amounts of Lactobacil-lus were observed in children with acute diarrhea than in healthy controls [median (interquartile range/IR): 1.52x103 (1.22x104) vs. 6.87x10 (2.41x102), respectively; proportion in percentage (from total bacteria population): 0.044% vs. 0.003%, respectively]. However, median (IR) Clostridium was significantly higher in healthy controls than in children with acute diarrhea [2.37x102 (4.64x103) vs. 4.67 (1.50x102), respectively, with proportion of 0.01% vs. 0.0001%, respectively]. Children who received probio tics had significantly higher count of Bifidobacterium compared to the placebo group [1.94x104 (4.97x104) vs. 1.74x103 (2.08x107), respectively, with proportion of 0.394% vs. 0.081%, respectively]. Conclusion This pilot study do not find evidence of dysbiosis in children with acute diarrhea. Group who received probiotic has higher Bifidobacterium count compared towards those who received placebo.
AB - Background Acute diarrhea is a common health problem in Indo-nesia. During acute diarrhea, changes in gut microbiota are marked by decrease beneficial microbes Bifidobacterium and Lactobacillus, and increased pathogenic bacteria Enterobacter and Clostridium. Such microbial imbalances are known as dysbiosis. Treatment with probiotics may help repair dysbiosis, quicken healing time, and decrease complications. Objective To assess for dysbiosis during acute diarrhea, and determine if it can be normalized by probiotic treatment. Methods This placebo-controlled, unblinded clinical trial was performed in Budhi Asih District Hospital, Jakarta, from January to March 2018. Twenty-four children age 6-24 months with acute diarrhea and 12 healthy children were enrolled. First fecal specimen was collected for all subjects and analyzed using non-culture real time PCR to count the population of Lactobacillus, Bifidobacterium, Enterobacter, Clostridium, and all bacteria. Children with diarrhea were assigned to probiotic or placebo treatment for 5 days and the second fecal specimen was analyzed two weeks after the diarrhea subsided. Results Prior to treatment, significant higher amounts of Lactobacil-lus were observed in children with acute diarrhea than in healthy controls [median (interquartile range/IR): 1.52x103 (1.22x104) vs. 6.87x10 (2.41x102), respectively; proportion in percentage (from total bacteria population): 0.044% vs. 0.003%, respectively]. However, median (IR) Clostridium was significantly higher in healthy controls than in children with acute diarrhea [2.37x102 (4.64x103) vs. 4.67 (1.50x102), respectively, with proportion of 0.01% vs. 0.0001%, respectively]. Children who received probio tics had significantly higher count of Bifidobacterium compared to the placebo group [1.94x104 (4.97x104) vs. 1.74x103 (2.08x107), respectively, with proportion of 0.394% vs. 0.081%, respectively]. Conclusion This pilot study do not find evidence of dysbiosis in children with acute diarrhea. Group who received probiotic has higher Bifidobacterium count compared towards those who received placebo.
KW - Acute diarrhea
KW - Dysbiosis
KW - Gastroenteritis
KW - Gut microbiota
KW - Probiotic
UR - http://www.scopus.com/inward/record.url?scp=85102193353&partnerID=8YFLogxK
U2 - 10.14238/pi60.2.2020.83-90
DO - 10.14238/pi60.2.2020.83-90
M3 - Article
AN - SCOPUS:85102193353
SN - 0030-9311
VL - 60
SP - 83
EP - 90
JO - Paediatrica Indonesiana(Paediatrica Indonesiana)
JF - Paediatrica Indonesiana(Paediatrica Indonesiana)
IS - 2
ER -
